PAVM

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

Wall Street analysts forecast PAVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAVM is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

PAVmed Inc revenue for the last quarter amounts to 5.00K USD, decreased -99.50 % YoY.

PAVmed Inc. EPS for the last quarter amounts to -0.29 USD, decreased -120.14 % YoY.

PAVmed Inc (PAVM) has 39 emplpoyees as of December 15 2025.

Today PAVM has the market capitalization of 9.79M USD.